New Insights in the Management of Congenital Adrenal Hyperplasia

  • 250

    Total views and downloads

About this Research Topic

Submission deadlines

  1. Manuscript Summary Submission Deadline 30 June 2025 | Manuscript Submission Deadline 30 November 2025

  2. This Research Topic is still accepting articles.

Background

Management of Congenital Adrenal Hyperplasia (CAH) due to 21- hydroxylase deficiency involves a delicate balance between risks associated with hyperandrogenemia and those associated with chronic glucocorticoid overexposure and continues to be a challenging task with multiple unmet needs. Glucocorticoids, administered not only to replace cortisol deficiency, but also to suppress adrenocorticotropic hormone (ACTH)-driven hyperandrogenism, are associated with lifelong disruption of the physiological circadian rhythm. Fatigue, obesity, insulin resistance, diabetes, impaired bone health, and psychological morbidity are attributed to the iatrogenic non-physiological cortisol profiles in these individuals resulting from typically used hydrocortisone replacement regimens. The evidence for impaired quality of life and poor health outcomes in individuals with CAH is rising and is likely related to both disease- and treatment-associated morbidity. (1-3)

Recent interventions aiming to achieve a more physiological cortisol profile in individuals with CAH provide hope for the patients, caregivers, and providers. Modified-release glucocorticoid preparations, corticotropin-releasing factor (CRF) 1 receptor antagonists, and ACTH-receptor antagonists have demonstrated some proof to the principle of improved androgen control with less glucocorticoids in clinical trials. (4-12) The application to clinical practice and whether the benefits are substantial or not remains to be confirmed particularly in the long-term.

It is not easy to quantify the disease burden and the anticipated benefit from new interventions on disease control and patient quality of life. More studies and data are required to recognize the different aspects of CAH burden and connect the findings to the potential benefits of such new interventions to the CAH community.

The CAH management landscape requires better utilization of available tools in achieving a better long-term quality of life. The aim of the article collection is to invite researchers and experts in the field to share their experience and enhance the available knowledge on CAH disease burden and views on current and emerging therapies.

We welcome original research articles, reviews, and other article types focusing on but not limited to:

• Advancements in Glucocorticoid Therapy: Evaluations of modified-release glucocorticoid preparations, CRF1 receptor antagonists, and ACTH-receptor antagonists in achieving more physiological cortisol profiles.

• Long-Term Health Outcomes in CAH: Studies exploring the impact of current and emerging treatments on metabolic health, bone density, cardiovascular risk, and psychological well-being.

• Quality of Life and Patient Perspectives: Research on the lived experiences of individuals with CAH, including the psychosocial burden and the impact of lifelong glucocorticoid therapy.

• Personalized Treatment Approaches: Investigations into precision medicine strategies, including genetic and biomarker-driven approaches for optimizing CAH management.

• Bridging the Gap Between Research and Clinical Practice: Studies assessing how recent therapeutic advancements translate into real-world clinical applications and long-term benefits.

• Novel Tools for Disease Burden Assessment: Development and validation of new metrics for quantifying disease burden and treatment effectiveness in individuals with CAH.


1. New MI, Lekarev O, Mancenido D, Parsa A, Yuen T. Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency. Genetic Steroid Disorders 2014. p. 29-51.

2. Porter J, Blair J, Ross RJ. Is physiological glucocorticoid replacement important in children? Arch Dis Child. 2017; 102:199-205.

3. Khattab A, Marshall I. Management of congenital adrenal hyperplasia: beyond conventional glucocorticoid therapy. Curr Opin Pediatr. 2019; 31:550-554.

4. Newfield RS, Sarafoglou K, Fechner PY, Nokoff NJ, Auchus RJ, Vogiatzi MG, Jeha GS, Giri N, Roberts E, Sturgeon J, Chan JL, Farber RH. Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2023; 108:2871-2878.

5. Auchus RJ, Sarafoglou K, Fechner PY, Vogiatzi MG, Imel EA, Davis SM, Giri N, Sturgeon J, Roberts E, Chan JL, Farber RH.. Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2022 Feb 17.

6. Sarafoglou K, Kim MS, Lodish M, Felner EI, Martinerie L, Nokoff NJ, Clemente M, Fechner PY, Vogiatzi MG, Speiser PW, Auchus RJ, Rosales GBG, Roberts E, Jeha GS, Farber RH, Chan JL; CAHtalyst Pediatric Trial Investigators. Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia. N Engl J Med. 2024; 391:493-503.

7. Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, Isidori AM, Rodien P, Srirangalingam U, Kiefer FW, Falhammar H, Merke DP, Reisch N, Sarafoglou K, Cutler GB Jr, Sturgeon J, Roberts E, Lin VH, Chan JL, Farber RH; CAHtalyst Adult Trial Investigators. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia. N Engl J Med. 2024; 391:504-514.

8. Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results From a12-Week, Phase 2, Open-Label Study
Richard J. Auchus, MD, PhD, Peter J. Trainer, MD, Kathryn Jean Lucas, MD3, et al
Poster: Annual Meeting of the Endocrine Society (ENDO); 6/03/2024.

9. Atumelnant (CRN04894) Induces Rapid and Sustained Reductions in Serum and Urine Cortisol in Patients With ACTH-Dependent Cushing Syndrome During a Phase 1b/2a, Single Center, 10-Day, Inpatient, Open-Label Study. Henrik Elenius, Raven McGlotten, Casey Moore, et al. Poster: Annual Meeting of the Endocrine Society (ENDO); 6/03/2024.

10. Merke, D. P., et al). Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2021;106: e2063-e2077.

11. Nowotny, H., et al. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. Endocrine 2021; 71:586-594.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

  • Case Report
  • Clinical Trial
  • Editorial
  • General Commentary
  • Hypothesis and Theory
  • Methods
  • Mini Review
  • Opinion
  • Original Research

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Keywords: Congenital adrenal hyperplasia, CAH, cortisol, glucocorticoids, 21-hydroxylase deficiency

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic editors

Frequently asked questions

  • Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

    Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

  • The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

    Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

  • As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

    A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

  • Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

    In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

  • Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

    As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

    Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

  • Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

    Check available article types here 

  • Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

    Suggest your topic here 

  • A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

    The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

  • As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

    You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

  • As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

  • If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

  • Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

  • Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

  • As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

    Find out more about our Research Topics

  • Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

    Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

  • In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.

Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.

Impact

  • 250Topic views
  • 20Article views
View impact